PharmiWeb

Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting. The IIT is ...
GQ

What’s Soft Cardio? Experts Explain Everyone’s Latest Fitness Obsession

Every now and then, fitness TikTok digs up something that’s been around forever and calls it a “trend.” Earlier this year, the honors went to zone 2 cardio, a relatively low-effort form of fat-burning ...
Pharmabiz

Faron Pharma expands bexmarilimab programme in solid tumours with a randomized phase I/II BEXAR IIT in metastatic soft-tissue sarcoma

Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, announces a significant expansion to scope of clinical trials where ...
Finanznachrichten

Faron Pharmaceuticals: Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting. TURKU, FI / ...